The global disseminated intravascular coagulation (DIC) treatment market is expected to garner a market value of US$ 500 million in 2023 and is expected to accumulate a market value of US$ 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for disseminated intravascular coagulation (DIC) treatment registered a CAGR of 4% in the historical period 2018 to 2022.
The Disseminated Intravascular Coagulation (DIC) Treatment market is a segment of the healthcare industry that deals with the effective management of Disseminated Intravascular Coagulation (DIC). The Disseminated Intravascular Coagulation (DIC) Treatment market offers a range of products and services for the management and treatment of DIC. The market for DIC treatments is largely driven by the increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications, as well as advancements in diagnostic and treatment technologies.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 500 Million |
| Anticipated Forecast Value (2033) | US$ 814.45 Million |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Disseminated Intravascular Coagulation (DIC) Treatment reflected a value of 4% during the historical period, 2018 to 2022.
The increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications that can lead to DIC is driving the demand for DIC treatments. Studies suggest that estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). Treatment for Disseminated Intravascular Coagulation (DIC) involves addressing the underlying condition that is causing the disorder, as well as treating the symptoms of DIC itself.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Disseminated Intravascular Coagulation (DIC) Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Disseminated Intravascular Coagulation (DIC) Treatments is fuelling the market growth. Thus, the market for Disseminated Intravascular Coagulation (DIC) Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increased Prevalence of Disseminated Intravascular Coagulation (DIC) in Elderly Population to Push the Market Growth
The global market for disseminated intravascular coagulation (DIC) treatment is driven by the growing advancements in treatment technologies, the development of new diagnostic technologies, and the availability of more effective treatments. In addition, increased awareness of DIC, especially amongst the geriatric population which is at higher risk of developing underlying conditions that can lead to DIC, has led to a higher healthcare expenditure globally contributing to the growth of the market. Furthermore, the prevalence of Disseminated Intravascular Coagulation (DIC) is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings and cater to the growing demand for minimally invasive treatments for DIC, by developing new, less invasive treatments.
In 2021, a new tool created by researchers to tackle disseminated intravascular coagulation (DIC) was announced. Although the technology was yet to undergo clinical trials, studies in rat models and on blood from DIC patients have shown promise. Brown and her team created a method using nanogel spheres. These spheres are specifically designed to attach to fibrin, the primary protein present in blood clots. By doing so, the spheres travel through the bloodstream and once they encounter a blood clot, they adhere to the fibrin. The goal is to find a clinical solution to this dilemma and the new tool, using nanogel spheres, offers promising results. The spheres are designed to bind to the main protein in clots, fibrin, and are loaded with tissue-type plasminogen activator, a drug that dissolves clots.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Disseminated Intravascular Coagulation (DIC) Treatment options.
Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, are expected to hinder the market growth. Furthermore, various alternative treatments for underlying conditions, such as chemotherapy for cancer or antibiotics for sepsis, can limit demand for DIC treatments.
Improvement in healthcare spending propelling growth of Disseminated Intravascular Coagulation (DIC) Treatment in Asia Pacific
The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, with a CAGR of 2.5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Disseminated Intravascular Coagulation (DIC) Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to healthcare. Increasing number of hospitals in India and China makes a promising market for the market worldwide.
Technological Advancements Shaping Landscape for Disseminated Intravascular Coagulation (DIC) Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
The Centre for Disease Control and Prevention (CDC), in its December 2022 update reported that, in 2021, the incidence of coronary heart disease and heart attack among adults over 18 years old in the United States was 4.9% and 3% respectively. The high prevalence of heart diseases in developed nations will drive the growth of the market. Additionally, the increasing number of research partnerships and favorable regulatory policies also play a significant role in driving the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
D-Dimer segment is expected to hold a major market share
The growing incidence of Venous Thromboembolism (VTE) and the increasing occurrence of pulmonary and cardiovascular diseases caused by blood clots are also contributing to the demand for D-dimer testing. The use of automated analyzers for D-dimer testing has increased in recent years and is expected to grow further in the future. Research has shown that these analyzers significantly reduce laboratory processing time and improve clinical decision making. Furthermore, ongoing R&D efforts to expand the use of analyzers also drives their usage.
Considering these figures, the D-Dimer diagnosis segment of Disseminated Intravascular Coagulation (DIC) is projected to push the market growth. Such a high prevalence of the disease is anticipated to bolster the demand for Disseminated Intravascular Coagulation (DIC) Treatment among the patient population over the coming years.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the DIC treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target disease.
Key players in the market include pharmaceutical companies such as Pfizer, Inc., Pfizer Inc., Roche Holding AG, Sanofi, Bayer AG and Johnson & Johnson, as well as healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 500 million |
| Market Value in 2033 | US$ 814.45 million |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
China, India, and Japan are key Asian countries in the market.
Hospital sector is gaining significant traction in the market.
A CAGR of 7% is expected for the DIC treatment market by 2033.
The DIC therapy market is currently valued at US$ 500 million.
The DIC therapy market is anticipated to reach US$ 814.45 million by 2033.
1. Executive Summary | Disseminated Intravascular Coagulation (DIC) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Medicines 5.3.2. Transfusions 5.3.3. Surgery 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 6.3.1. Partial Thromboplastin Time (PTT) 6.3.2. Prothrombin Time (PT) 6.3.3. Fibrinogen Blood Test 6.3.4. D-dimer 6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-Users , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users , 2023 to 2033 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Homecare 7.4. Y-o-Y Growth Trend Analysis By End-Users , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-Users , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Diagnosis 9.2.4. By End-Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Diagnosis 9.3.4. By End-Users 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Diagnosis 10.2.4. By End-Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Diagnosis 10.3.4. By End-Users 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Treatment 11.2.3. By Diagnosis 11.2.4. By End-Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Diagnosis 11.3.4. By End-Users 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Treatment 12.2.3. By Diagnosis 12.2.4. By End-Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Diagnosis 12.3.4. By End-Users 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment 13.2.3. By Diagnosis 13.2.4. By End-Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Diagnosis 13.3.4. By End-Users 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Treatment 14.2.3. By Diagnosis 14.2.4. By End-Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Diagnosis 14.3.4. By End-Users 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Treatment 15.2.3. By Diagnosis 15.2.4. By End-Users 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment 15.3.3. By Diagnosis 15.3.4. By End-Users 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Treatment 16.1.2.2. By Diagnosis 16.1.2.3. By End-Users 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Treatment 16.2.2.2. By Diagnosis 16.2.2.3. By End-Users 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Treatment 16.3.2.2. By Diagnosis 16.3.2.3. By End-Users 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Treatment 16.4.2.2. By Diagnosis 16.4.2.3. By End-Users 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Treatment 16.5.2.2. By Diagnosis 16.5.2.3. By End-Users 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Treatment 16.6.2.2. By Diagnosis 16.6.2.3. By End-Users 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Treatment 16.7.2.2. By Diagnosis 16.7.2.3. By End-Users 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Treatment 16.8.2.2. By Diagnosis 16.8.2.3. By End-Users 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Treatment 16.9.2.2. By Diagnosis 16.9.2.3. By End-Users 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Treatment 16.10.2.2. By Diagnosis 16.10.2.3. By End-Users 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Treatment 16.11.2.2. By Diagnosis 16.11.2.3. By End-Users 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Treatment 16.12.2.2. By Diagnosis 16.12.2.3. By End-Users 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Treatment 16.13.2.2. By Diagnosis 16.13.2.3. By End-Users 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Treatment 16.14.2.2. By Diagnosis 16.14.2.3. By End-Users 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Treatment 16.15.2.2. By Diagnosis 16.15.2.3. By End-Users 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Treatment 16.16.2.2. By Diagnosis 16.16.2.3. By End-Users 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Treatment 16.17.2.2. By Diagnosis 16.17.2.3. By End-Users 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Treatment 16.18.2.2. By Diagnosis 16.18.2.3. By End-Users 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Treatment 16.19.2.2. By Diagnosis 16.19.2.3. By End-Users 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Treatment 16.20.2.2. By Diagnosis 16.20.2.3. By End-Users 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Treatment 16.21.2.2. By Diagnosis 16.21.2.3. By End-Users 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Treatment 17.3.3. By Diagnosis 17.3.4. By End-Users 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. F. Hoffmann-La Roche Ltd. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Mylan N.V. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Teva Pharmaceutical Industries Ltd. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Sanofi 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Pfizer Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. GlaxoSmithKline plc 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Novartis AG 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Bayer AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Eli Lilly and Company 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Merck & Co., Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Allergan 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. AbbVie Inc. 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Merck KGaA 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. Hikma Pharmaceuticals PLC 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Disseminated Intravascular Coagulation (DIC) Treatment Market
